<p>根据其最近向美国证券交易委员会提交的 13F 表格，World Investment Advisors 在第四季度将其在 CVS Health Corporation（纽约证券交易所代码：CVS - 免费报告）的持股增加了 36.5%。该基金在此期间购买了 19,623 股后，持有 73,409 股该药房运营商的股票。World Investment Advisors 在 CVS Health 的持股在最近一个季度末价值为 5,826,000 美元。</p>
<ul>
<li>3 只医疗保健股票将受益于这项重大法案</li>
</ul>
<p>其他几家机构投资者也买卖了 CVS 的股票。凯通国际资产管理有限公司在第三季度将其在 CVS Health 的持仓提高了 407.2%。凯通国际资产管理有限公司目前持有 350 股该药房运营商的股票，价值 26,000 美元，此前在上个季度又购买了 281 股。Ares Financial Consulting LLC 在第四季度购买了 CVS Health 的新头寸，价值 29,000 美元。Dogwood Wealth Management LLC 在第四季度将其在 CVS Health 的持仓提高了 93.7%。Dogwood Wealth Management LLC 目前持有 370 股该药房运营商的股票，价值 29,000 美元，此前在上个季度又购买了 179 股。GoalVest Advisory LLC 在第四季度购买了 CVS Health 的新头寸，价值 32,000 美元。最后，Financial Consulate Inc.在第四季度将其在 CVS Health 的持仓提高了 99.6%。Financial Consulate Inc.目前持有 499 股该药房运营商的股票，价值 40,000 美元，此前在上个季度又购买了 249 股。机构投资者持有该公司 80.66% 的股票。</p>
<h2>CVS Health 价格表现</h2>
<p>CVS 股票在周四开盘价为 98.14 美元。该股票的 50 日移动平均价格为 78.07 美元，200 日移动平均价格为 78.36 美元。CVS Health Corporation 的 52 周低点为 58.35 美元，52 周高点为 98.22 美元。该公司的债务与股本比率为 0.78，速动比率为 0.66，流动比率为 0.87。该公司的市值为 1,252.2 亿美元，市盈率为 43.24，市盈增长比率为 0.93，贝塔值为 0.60。</p>
<ul>
<li>这只 ETF 证明医疗保健复苏是真实的</li>
</ul>
<p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）最后一次公布季度财报是在 5 月 6 日，星期三。该药房运营商报告季度每股收益为 2.57 美元，超出市场共识预期的 2.21 美元，超出幅度为 0.36 美元。CVS Health 的股本回报率为 11.88%，净利润率为 0.72%。该公司季度收入为 1,004.3 亿美元，而市场共识预期为 949.9 亿美元。在去年同期，该公司每股收益为 2.25 美元。CVS Health 的季度收入同比增长 6.2%。CVS Health 已将其 2026 财年的每股收益指引设定为 7.300-7.500。作为一个整体，卖方分析师预测 CVS Health Corporation 在当前年度将发布每股收益为 7.46。</p>
<h2>CVS Health 股息公告</h2>
<p>该公司最近还披露了季度股息，该股息于 5 月 4 日，星期一支付。4 月 23 日登记的投资者获得每股 0.665 美元的股息。除息日期为 4 月 23 日，星期四。这相当于年化股息为 2.66 美元，收益率为 2.7%。CVS Health 的股息支付比率（DPR）目前为 117.18%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>随着收入增长，CVS Health 股价上涨，股息保持强劲</li>
</ul>
<p>几位股票分析师对 CVS 股票发表了评论。Weiss Ratings 在 5 月 8 日，星期五的研究报告中重申了对 CVS Health 股票的 “持有（c）” 评级。Leerink Partners 在 3 月 5 日，星期四的研究报告中重申了 “跑赢大盘” 评级，并对 CVS Health 股票设定了 98.00 美元的目标价。DA Davidson 在 5 月 7 日，星期四的研究报告中将 CVS Health 股票的目标价从 80.00 美元提高至 100.00 美元，并给予该公司 “买入” 评级。巴克莱在 5 月 7 日，星期四的研究报告中将 CVS Health 股票的目标价从 93.00 美元提高至 101.00 美元，并给予该公司 “增持” 评级。最后，高盛集团在 2 月 12 日，星期四的研究报告中将 CVS Health 股票的目标价从 95.00 美元提高至 97.00 美元，并给予该股票 “买入” 评级。22 位研究分析师对该股票给予了买入评级，4 位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 97.00 美元。</p>
<p><strong>查看我们关于 CVS 的最新报告</strong></p>
<h2>影响 CVS Health 的关键头条新闻</h2>
<p>以下是本周影响 CVS Health 的关键新闻故事：</p>
<ul>
<li>积极情绪：摩根大通将 CVS Health 的目标股价从 101 美元上调至 111 美元，并维持超配评级，而桑福德·C·伯恩斯坦将目标从 94 美元上调至 106 美元，并维持跑赢大盘，显示出分析师的持续信心。文章标题</li>
<li>积极情绪：CVS Health 因强劲的第一季度业绩和改善的盈利能力而受到关注，最近的报道指出，该股票在超出盈利和收入预期后达到了新的 52 周高点。文章标题</li>
<li>积极情绪：分析师和市场评论也指出 CVS 是排名靠前的增长/分红股票，这可能有助于提升对该股票的情绪。文章标题</li>
<li>中性情绪：CVS 的 Omnicare 子公司获得破产法庭批准，将其业务出售给 GenieRx，这一步骤应有助于 CVS 继续重塑该部门，尽管这更多是一个重组故事，而不是直接的盈利驱动因素。文章标题</li>
<li>中性情绪：CVS 还宣布了与人工智能和 MinuteClinic 相关的举措，包括企业人工智能的认可和减肥项目的更新，这些支持了公司的创新叙事，但不太可能成为立即的股票催化剂。文章标题</li>
<li>消极情绪：在最新一批中没有出现重大新的消极头条；然而，投资者可能仍在关注重组、处方变更和更广泛的医疗保健利润压力的执行风险。</li>
</ul>
<h2>内部人士下注</h2>
<p>在其他 CVS Health 新闻中，执行副总裁 Tilak Mandadi 于 5 月 8 日星期五出售了 69,551 股公司的股票。股票以平均价格 89.58 美元出售，总价值为 6,230,378.58 美元。出售完成后，该执行副总裁直接持有 10,133 股公司股票，价值 907,714.14 美元。此次交易使其持股减少了 87.28%。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接获取。内部人士持有 0.85% 的股票。</p>
<h2>CVS Health 公司简介</h2>
<p>（免费报告）</p>
<p>CVS Health Corporation 是一家多元化的医疗保健公司，运营着一个大型零售药房网络、药房福利管理服务和医疗解决方案。公司总部位于罗德岛州的伍恩索克特，追溯到 20 世纪 60 年代初，已发展成为处方药、非处方产品、临床服务和健康保险产品的综合提供商。其运营模式结合了零售药房和店内诊所与更广泛的药房和健康计划能力。</p>
<p>主要业务活动包括 CVS 药房零售业务、MinuteClinic 步入式医疗诊所和提供扩展临床服务的 HealthHUB 地点。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 CVS Health</li>
<li>Oklo 股票可能准备再次大幅上涨</li>
<li>D-Wave 的财报看起来疲弱，但投资者可能忽视了这一点</li>
<li>随着人工智能反馈循环的加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士出售</li>
</ul>
<p><strong>想看看其他对 CVS 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取 CVS Health Corporation（NYSE:CVS - 免费报告）的最新 13F 备案和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CVS Health 吗？</h2>
<p>在考虑 CVS Health 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 CVS Health 并不在名单上。</p>
<p>虽然 CVS Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

西维斯

<p>世界投资顾问在第四季度将其在 CVS Health Corporation 的持股增加了 36.5%，目前持有 73,409 股，价值 583 万美元。其他机构投资者也提高了他们的持股比例，其中 Caitong International 和 Dogwood Wealth Management 的增幅尤为显著。CVS Health 的股票开盘价为 98.14 美元，市值为 1252.2 亿美元，市盈率为 43.24。该公司报告的季度每股收益为 2.57 美元，超出预期，并宣布每股派息 0.665 美元。分析师维持 “适度买入” 的共识评级，平均目标价为 97.00 美元</p>

<p>World Investment Advisors increased its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 36.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 73,409 shares of the pharmacy operator's stock after purchasing an additional 19,623 shares during the period. World Investment Advisors' holdings in CVS Health were worth $5,826,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据其最近向美国证券交易委员会提交的 13F 表格，World Investment Advisors 在第四季度将其在 CVS Health Corporation（纽约证券交易所代码：CVS - 免费报告）的持股增加了 36.5%。该基金在此期间购买了 19,623 股后，持有 73,409 股该药房运营商的股票。World Investment Advisors 在 CVS Health 的持股在最近一个季度末价值为 5,826,000 美元。</p>
</div><ul>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只医疗保健股票将受益于这项重大法案</li>
</ul>
</div><p>Several other institutional investors have also bought and sold shares of CVS. Caitong International Asset Management Co. Ltd lifted its position in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares during the last quarter. Ares Financial Consulting LLC bought a new position in CVS Health during the fourth quarter valued at $29,000. Dogwood Wealth Management LLC lifted its position in CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator's stock valued at $29,000 after purchasing an additional 179 shares during the last quarter. GoalVest Advisory LLC bought a new position in CVS Health during the fourth quarter valued at $32,000. Finally, Financial Consulate Inc. lifted its position in CVS Health by 99.6% during the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator's stock valued at $40,000 after purchasing an additional 249 shares during the last quarter. Institutional investors own 80.66% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者也买卖了 CVS 的股票。凯通国际资产管理有限公司在第三季度将其在 CVS Health 的持仓提高了 407.2%。凯通国际资产管理有限公司目前持有 350 股该药房运营商的股票，价值 26,000 美元，此前在上个季度又购买了 281 股。Ares Financial Consulting LLC 在第四季度购买了 CVS Health 的新头寸，价值 29,000 美元。Dogwood Wealth Management LLC 在第四季度将其在 CVS Health 的持仓提高了 93.7%。Dogwood Wealth Management LLC 目前持有 370 股该药房运营商的股票，价值 29,000 美元，此前在上个季度又购买了 179 股。GoalVest Advisory LLC 在第四季度购买了 CVS Health 的新头寸，价值 32,000 美元。最后，Financial Consulate Inc.在第四季度将其在 CVS Health 的持仓提高了 99.6%。Financial Consulate Inc.目前持有 499 股该药房运营商的股票，价值 40,000 美元，此前在上个季度又购买了 249 股。机构投资者持有该公司 80.66% 的股票。</p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 价格表现</h2>
</div><p>Shares of CVS stock opened at $98.14 on Thursday. The stock has a 50 day moving average price of $78.07 and a 200 day moving average price of $78.36. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $98.22. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $125.22 billion, a P/E ratio of 43.24, a P/E/G ratio of 0.93 and a beta of 0.60.</p>
<div class="lb-trans"><p>CVS 股票在周四开盘价为 98.14 美元。该股票的 50 日移动平均价格为 78.07 美元，200 日移动平均价格为 78.36 美元。CVS Health Corporation 的 52 周低点为 58.35 美元，52 周高点为 98.22 美元。该公司的债务与股本比率为 0.78，速动比率为 0.66，流动比率为 0.87。该公司的市值为 1,252.2 亿美元，市盈率为 43.24，市盈增长比率为 0.93，贝塔值为 0.60。</p>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>这只 ETF 证明医疗保健复苏是真实的</li>
</ul>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the company posted $2.25 EPS. CVS Health's quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current year.</p>
<div class="lb-trans"><p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）最后一次公布季度财报是在 5 月 6 日，星期三。该药房运营商报告季度每股收益为 2.57 美元，超出市场共识预期的 2.21 美元，超出幅度为 0.36 美元。CVS Health 的股本回报率为 11.88%，净利润率为 0.72%。该公司季度收入为 1,004.3 亿美元，而市场共识预期为 949.9 亿美元。在去年同期，该公司每股收益为 2.25 美元。CVS Health 的季度收入同比增长 6.2%。CVS Health 已将其 2026 财年的每股收益指引设定为 7.300-7.500。作为一个整体，卖方分析师预测 CVS Health Corporation 在当前年度将发布每股收益为 7.46。</p>
</div><h2>CVS Health Dividend Announcement</h2>
<div class="lb-trans"><h2>CVS Health 股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health's dividend payout ratio (DPR) is presently 117.18%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，该股息于 5 月 4 日，星期一支付。4 月 23 日登记的投资者获得每股 0.665 美元的股息。除息日期为 4 月 23 日，星期四。这相当于年化股息为 2.66 美元，收益率为 2.7%。CVS Health 的股息支付比率（DPR）目前为 117.18%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>随着收入增长，CVS Health 股价上涨，股息保持强劲</li>
</ul>
</div><p>Several equities analysts have commented on CVS shares. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of CVS Health in a research report on Friday, May 8th. Leerink Partners restated an &#34;outperform&#34; rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. DA Davidson boosted their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, May 7th. Barclays increased their target price on shares of CVS Health from $93.00 to $101.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group lifted their price target on shares of CVS Health from $95.00 to $97.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $97.00.</p>
<div class="lb-trans"><p>几位股票分析师对 CVS 股票发表了评论。Weiss Ratings 在 5 月 8 日，星期五的研究报告中重申了对 CVS Health 股票的 “持有（c）” 评级。Leerink Partners 在 3 月 5 日，星期四的研究报告中重申了 “跑赢大盘” 评级，并对 CVS Health 股票设定了 98.00 美元的目标价。DA Davidson 在 5 月 7 日，星期四的研究报告中将 CVS Health 股票的目标价从 80.00 美元提高至 100.00 美元，并给予该公司 “买入” 评级。巴克莱在 5 月 7 日，星期四的研究报告中将 CVS Health 股票的目标价从 93.00 美元提高至 101.00 美元，并给予该公司 “增持” 评级。最后，高盛集团在 2 月 12 日，星期四的研究报告中将 CVS Health 股票的目标价从 95.00 美元提高至 97.00 美元，并给予该股票 “买入” 评级。22 位研究分析师对该股票给予了买入评级，4 位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 97.00 美元。</p>
</div><p><strong>View Our Latest Report on CVS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CVS 的最新报告</strong></p>
</div><h2>Key Headlines Impacting CVS Health</h2>
<div class="lb-trans"><h2>影响 CVS Health 的关键头条新闻</h2>
</div><p>Here are the key news stories impacting CVS Health this week:</p>
<div class="lb-trans"><p>以下是本周影响 CVS Health 的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: JPMorgan raised its price target on CVS Health to $111 from $101 and kept an overweight rating, while Sanford C. Bernstein lifted its target to $106 from $94 and maintained outperform, signaling continued analyst confidence. Article Title</li>
<li>Positive Sentiment: CVS Health has been highlighted for strong Q1 results and improving profitability, with recent coverage noting the stock reached a new 52-week high after beating earnings and revenue expectations. Article Title</li>
<li>Positive Sentiment: Analysts and market commentary are also pointing to CVS as a top-ranked growth/dividend name, which may be helping sentiment around the stock. Article Title</li>
<li>Neutral Sentiment: CVS’s Omnicare subsidiary won bankruptcy court approval to sell its business to GenieRx, a step that should help CVS continue reshaping that unit, though it is more of a restructuring story than a direct earnings driver. Article Title</li>
<li>Neutral Sentiment: CVS also announced AI and MinuteClinic-related initiatives, including recognition for enterprise AI and a weight-loss program update, which support the company’s innovation narrative but are not likely immediate stock catalysts. Article Title</li>
<li>Negative Sentiment: There were no major fresh negative headlines in the latest batch; however, investors may still be watching execution risk around restructuring, formulary changes, and broader healthcare margin pressures.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：摩根大通将 CVS Health 的目标股价从 101 美元上调至 111 美元，并维持超配评级，而桑福德·C·伯恩斯坦将目标从 94 美元上调至 106 美元，并维持跑赢大盘，显示出分析师的持续信心。文章标题</li>
<li>积极情绪：CVS Health 因强劲的第一季度业绩和改善的盈利能力而受到关注，最近的报道指出，该股票在超出盈利和收入预期后达到了新的 52 周高点。文章标题</li>
<li>积极情绪：分析师和市场评论也指出 CVS 是排名靠前的增长/分红股票，这可能有助于提升对该股票的情绪。文章标题</li>
<li>中性情绪：CVS 的 Omnicare 子公司获得破产法庭批准，将其业务出售给 GenieRx，这一步骤应有助于 CVS 继续重塑该部门，尽管这更多是一个重组故事，而不是直接的盈利驱动因素。文章标题</li>
<li>中性情绪：CVS 还宣布了与人工智能和 MinuteClinic 相关的举措，包括企业人工智能的认可和减肥项目的更新，这些支持了公司的创新叙事，但不太可能成为立即的股票催化剂。文章标题</li>
<li>消极情绪：在最新一批中没有出现重大新的消极头条；然而，投资者可能仍在关注重组、处方变更和更广泛的医疗保健利润压力的执行风险。</li>
</ul>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business's stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company's stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 CVS Health 新闻中，执行副总裁 Tilak Mandadi 于 5 月 8 日星期五出售了 69,551 股公司的股票。股票以平均价格 89.58 美元出售，总价值为 6,230,378.58 美元。出售完成后，该执行副总裁直接持有 10,133 股公司股票，价值 907,714.14 美元。此次交易使其持股减少了 87.28%。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接获取。内部人士持有 0.85% 的股票。</p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.</p>
<div class="lb-trans"><p>CVS Health Corporation 是一家多元化的医疗保健公司，运营着一个大型零售药房网络、药房福利管理服务和医疗解决方案。公司总部位于罗德岛州的伍恩索克特，追溯到 20 世纪 60 年代初，已发展成为处方药、非处方产品、临床服务和健康保险产品的综合提供商。其运营模式结合了零售药房和店内诊所与更广泛的药房和健康计划能力。</p>
</div><p>Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.</p>
<div class="lb-trans"><p>主要业务活动包括 CVS 药房零售业务、MinuteClinic 步入式医疗诊所和提供扩展临床服务的 HealthHUB 地点。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 CVS Health</li>
<li>Oklo 股票可能准备再次大幅上涨</li>
<li>D-Wave 的财报看起来疲弱，但投资者可能忽视了这一点</li>
<li>随着人工智能反馈循环的加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士出售</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 CVS 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取 CVS Health Corporation（NYSE:CVS - 免费报告）的最新 13F 备案和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CVS Health 吗？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CVS Health 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 CVS Health 并不在名单上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CVS Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

World Investment Advisors Grows Position in CVS Health Corporation $CVS

Market Beat

巴克莱银行

高盛

摩根大通

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

世界投资顾问公司扩大了在 CVS Health Corporation $CVS 的持仓